- Joined
- Feb 25, 2011
- Messages
- 2,500
For those that have been in the game awhile we've seen it before. Raw Deal, Gear Grinder, in 2010-12 the crackdown on research sites selling Cialis and Viagra, NAC pulled by the Pharma companies lobbying during the Pandemic, etc, etc, etc. Looks like it's time for another. Now it's the Safe Supplement Act which apparently has support of both parties.
This latest one is due to the upcoming release of Reta by Big Pharma. Pharma has been pushing very hard to make sure their advertising of GLP's isn't an advertising platform for the RUO (research use only) sites. If you noticed lately, many of the big hitters on the RUO playground have already pulled their GLP's and SS31. It is up in the air if they are going to go after other peps such as BPC, GHK-cu, etc. Since these are not patented hopefully they will stick around.
Apparently they are also going to be fining CC processors up to 500K as well to put an extra kink in things. From my point of view, I think that they will make some examples of the get go. From there we'll see what happens. We all know how to source from other avenues so it mostly won't jam many here up but it will certainly jam up the moms at the country club who have been buying RUO.
The SAFE Drugs Act of 2025 (H.R. 6509) isn't a direct "ban" on all peptides but aims to tighten regulations on compounded drugs, including peptides like GLP-1s (semaglutide, tirzepatide), by stopping misleading claims and enhancing FDA oversight, meaning peptides sold as unapproved "generics" or without proper testing face stricter scrutiny and potential removal from compounding lists, rather than an outright ban on all peptide uses. Its goal is to stop dangerous, untested mass-compounded products, not necessarily all legitimate, individually prescribed peptides, but it significantly increases FDA's power to target these substances.
Key Points:
Focus on Compounding: The bill targets "fraudulent and experimental" mass-compounded drugs, which often include peptides, by demanding stricter quality, inspections, and reporting.
FDA Enforcement: It empowers the FDA to act against companies making false claims (e.g., saying compounded peptides are the same as FDA-approved drugs) and selling risky products.
Not a Total Ban (Yet): Peptides themselves aren't banned, but if they don't meet new standards or are marketed deceptively, they face crackdown, potentially limiting their availability for compounding.
Context: This follows increased FDA warning letters in 2025 to peptide compounders, highlighting safety concerns with unregulated, compounded GLP-1s and other peptides.
In essence: H.R. 6509 seeks to clean up the gray market for compounded peptides, making it harder to sell them as cheap alternatives to brand-name drugs, but the final impact depends on FDA implementation and potential future rulings.
This latest one is due to the upcoming release of Reta by Big Pharma. Pharma has been pushing very hard to make sure their advertising of GLP's isn't an advertising platform for the RUO (research use only) sites. If you noticed lately, many of the big hitters on the RUO playground have already pulled their GLP's and SS31. It is up in the air if they are going to go after other peps such as BPC, GHK-cu, etc. Since these are not patented hopefully they will stick around.
Apparently they are also going to be fining CC processors up to 500K as well to put an extra kink in things. From my point of view, I think that they will make some examples of the get go. From there we'll see what happens. We all know how to source from other avenues so it mostly won't jam many here up but it will certainly jam up the moms at the country club who have been buying RUO.
The SAFE Drugs Act of 2025 (H.R. 6509) isn't a direct "ban" on all peptides but aims to tighten regulations on compounded drugs, including peptides like GLP-1s (semaglutide, tirzepatide), by stopping misleading claims and enhancing FDA oversight, meaning peptides sold as unapproved "generics" or without proper testing face stricter scrutiny and potential removal from compounding lists, rather than an outright ban on all peptide uses. Its goal is to stop dangerous, untested mass-compounded products, not necessarily all legitimate, individually prescribed peptides, but it significantly increases FDA's power to target these substances.
Key Points:
Focus on Compounding: The bill targets "fraudulent and experimental" mass-compounded drugs, which often include peptides, by demanding stricter quality, inspections, and reporting.
FDA Enforcement: It empowers the FDA to act against companies making false claims (e.g., saying compounded peptides are the same as FDA-approved drugs) and selling risky products.
Not a Total Ban (Yet): Peptides themselves aren't banned, but if they don't meet new standards or are marketed deceptively, they face crackdown, potentially limiting their availability for compounding.
Context: This follows increased FDA warning letters in 2025 to peptide compounders, highlighting safety concerns with unregulated, compounded GLP-1s and other peptides.
In essence: H.R. 6509 seeks to clean up the gray market for compounded peptides, making it harder to sell them as cheap alternatives to brand-name drugs, but the final impact depends on FDA implementation and potential future rulings.
